More recently, our group showed that FOXC1 mRNA and protein levels were significantly lower in primary marrow samples from APL patients, as compared to samples obtained from patients with other AML subtypes, and normal CD34+ hematopoietic cells [42]. Here, FOXC1 is linked to acute myeloid leukemia.